135 related articles for article (PubMed ID: 34719075)
1. Dipeptidyl peptidase-8 induces sorafenib resistance via binding with c-Rel to mediate NF-κB signaling in hepatocellular carcinoma.
Liu HF; Xie YK; Zhong BY; Zhang JH; Song CX; Liu YW; Yang Y; Xie BH
Cell Biol Int; 2022 Feb; 46(2):213-221. PubMed ID: 34719075
[TBL] [Abstract][Full Text] [Related]
2. Amplification of DDR2 mediates sorafenib resistance through NF-κB/c-Rel signaling in hepatocellular carcinoma.
Liu QQ; Liu YW; Xie YK; Zhang JH; Song CX; Wang JZ; Xie BH
Cell Biol Int; 2021 Sep; 45(9):1906-1916. PubMed ID: 33969575
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 1A2 overcomes nuclear factor kappa B-mediated sorafenib resistance in hepatocellular carcinoma.
Yu J; Wang N; Gong Z; Liu L; Yang S; Chen GG; Lai PBS
Oncogene; 2021 Jan; 40(3):492-507. PubMed ID: 33184472
[TBL] [Abstract][Full Text] [Related]
4. Minichromosome maintenance 3 promotes hepatocellular carcinoma radioresistance by activating the NF-κB pathway.
Yang Q; Xie B; Tang H; Meng W; Jia C; Zhang X; Zhang Y; Zhang J; Li H; Fu B
J Exp Clin Cancer Res; 2019 Jun; 38(1):263. PubMed ID: 31208444
[TBL] [Abstract][Full Text] [Related]
5. Aurora-a confers radioresistance in human hepatocellular carcinoma by activating NF-κB signaling pathway.
Shen ZT; Chen Y; Huang GC; Zhu XX; Wang R; Chen LB
BMC Cancer; 2019 Nov; 19(1):1075. PubMed ID: 31703572
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor α-induced protein 1 as a novel tumor suppressor through selective downregulation of CSNK2B blocks nuclear factor-κB activation in hepatocellular carcinoma.
Xiao Y; Huang S; Qiu F; Ding X; Sun Y; Wei C; Hu X; Wei K; Long S; Xie L; Xun Y; Chen W; Zhang Z; Liu N; Xiang S
EBioMedicine; 2020 Jan; 51():102603. PubMed ID: 31901862
[TBL] [Abstract][Full Text] [Related]
7. The lncARSR/PTEN/Akt/nuclear factor-kappa B feedback regulatory loop contributes to doxorubicin resistance in hepatocellular carcinoma.
Li Y; Li J; Chen H; Wang J; Jiang L; Tan X
J Biochem Mol Toxicol; 2022 Sep; 36(9):e23119. PubMed ID: 35678308
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms of HCG18 in the sorafenib resistance of hepatocellular carcinoma.
Li H; Hu J; Qiu L; Wu Y; Zhong B; Ye R; Xie B
Anticancer Drugs; 2024 Jan; 35(1):55-62. PubMed ID: 37823256
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
[TBL] [Abstract][Full Text] [Related]
10. Selenium nanoparticles overcomes sorafenib resistance in thioacetamide induced hepatocellular carcinoma in rats by modulation of mTOR, NF-κB pathways and LncRNA-AF085935/GPC3 axis.
Al-Noshokaty TM; Mesbah NM; Abo-Elmatty DM; Abulsoud AI; Abdel-Hamed AR
Life Sci; 2022 Aug; 303():120675. PubMed ID: 35640776
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-138-1-3p sensitizes sorafenib to hepatocellular carcinoma by targeting PAK5 mediated β-catenin/ABCB1 signaling pathway.
Li TT; Mou J; Pan YJ; Huo FC; Du WQ; Liang J; Wang Y; Zhang LS; Pei DS
J Biomed Sci; 2021 Aug; 28(1):56. PubMed ID: 34340705
[TBL] [Abstract][Full Text] [Related]
12. Regulation of HSP27 on NF-kappaB pathway activation may be involved in metastatic hepatocellular carcinoma cells apoptosis.
Guo K; Kang NX; Li Y; Sun L; Gan L; Cui FJ; Gao MD; Liu KY
BMC Cancer; 2009 Mar; 9():100. PubMed ID: 19331697
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells.
Urbanik T; Köhler BC; Boger RJ; Wörns MA; Heeger S; Otto G; Hövelmeyer N; Galle PR; Schuchmann M; Waisman A; Schulze-Bergkamen H
Int J Oncol; 2011 Jan; 38(1):121-31. PubMed ID: 21109933
[TBL] [Abstract][Full Text] [Related]
15. Regulation of dipeptidyl peptidase 8 and 9 expression in activated lymphocytes and injured liver.
Chowdhury S; Chen Y; Yao TW; Ajami K; Wang XM; Popov Y; Schuppan D; Bertolino P; McCaughan GW; Yu DM; Gorrell MD
World J Gastroenterol; 2013 May; 19(19):2883-93. PubMed ID: 23704821
[TBL] [Abstract][Full Text] [Related]
16. Lenvatinib Synergistically Promotes Radiation Therapy in Hepatocellular Carcinoma by Inhibiting Src/STAT3/NF-κB-Mediated Epithelial-Mesenchymal Transition and Metastasis.
Weng YS; Chiang IT; Tsai JJ; Liu YC; Hsu FT
Int J Radiat Oncol Biol Phys; 2023 Mar; 115(3):719-732. PubMed ID: 36245124
[TBL] [Abstract][Full Text] [Related]
17. SETD1A augments sorafenib primary resistance via activating YAP in hepatocellular carcinoma.
Wu J; Chai H; Li F; Ren Q; Gu Y
Life Sci; 2020 Nov; 260():118406. PubMed ID: 32918976
[TBL] [Abstract][Full Text] [Related]
18. Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice.
Lo J; Lau EY; Ching RH; Cheng BY; Ma MK; Ng IO; Lee TK
Hepatology; 2015 Aug; 62(2):534-45. PubMed ID: 25902734
[TBL] [Abstract][Full Text] [Related]
19. YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin.
Sun T; Mao W; Peng H; Wang Q; Jiao L
Cell Oncol (Dordr); 2021 Jun; 44(3):689-699. PubMed ID: 33655469
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model.
Chen JC; Chuang HY; Hsu FT; Chen YC; Chien YC; Hwang JJ
Oncotarget; 2016 Dec; 7(51):85450-85463. PubMed ID: 27863427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
